Cargando…

Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A(1)chieve study

AIM: To explore the clinical safety and effectiveness of insulin detemir (IDet) in a subgroup of Indian patients with type 2 diabetes (T2D) switched from either insulin glargine (IGlar) or neutral protamine Hagedorn (NPH) insulin in the 24-week, non-interventional A(1)chieve study. MATERIALS AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wangnoo, Subhash Kumar, Ghosal, Samit, Akhtar, Shahid, Shetty, Raman, Tripathi, Sudhir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171898/ https://www.ncbi.nlm.nih.gov/pubmed/25285292 http://dx.doi.org/10.4103/2230-8210.139239

Ejemplares similares

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Tamil Nadu cohort of the A(1)chieve study
por: Shunmugavelu, M., et al.
Publicado: (2013)

Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey
por: Satman, Ilhan, et al.
Publicado: (2013)

A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
por: Hod, Moshe, et al.
Publicado: (2014)

Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study
por: ji, Jing, et al.
Publicado: (2020)

A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus
por: Liu, Min, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
por: Morales, Cristóbal, et al.
Publicado: (2015)

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes
por: Home, P D, et al.
Publicado: (2015)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Delhi cohort of the A(1)chieve study
por: Tripathi, Sudhir, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Karnataka cohort of the A(1)chieve study
por: Deshpande, Neeta, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kolkata cohort of the A(1)chieve study
por: Majumder, Anirban, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the West India cohort of the A(1)chieve study
por: Jain, Sunil M., et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Andhra Pradesh cohort of the A(1)chieve study
por: Abubaker, Mohammed, et al.
Publicado: (2013)

Replacement of neutral protamine Hagedorn insulin with the long‐acting insulin analogue, detemir, improves glycemic control without weight gain in basal–bolus insulin therapy in Japanese patients with type 1 diabetes
por: Hayakawa, Taro, et al.
Publicado: (2011)

Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach
por: Pollock, Richard F, et al.
Publicado: (2018)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North India cohort of the A(1)chieve study
por: Kumar, Surender, et al.
Publicado: (2013)

Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India
por: Wangnoo, Subhash Kumar, et al.
Publicado: (2016)

Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study
por: Wang, Li, et al.
Publicado: (2013)

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
por: Rosenstock, J., et al.
Publicado: (2009)

Basal Supplementation of Insulin Lispro Protamine Suspension Versus Insulin Glargine and Detemir for Type 2 Diabetes: Meta-analysis of randomized controlled trials
por: Esposito, Katherine, et al.
Publicado: (2012)

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study
por: Rosenstock, J., et al.
Publicado: (2009)

Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study
por: Wolnik, B., et al.
Publicado: (2020)

Safety and Effectiveness of Insulin Detemir in Different Age-Groups in the A(1)chieve Study
por: Malek, Rachid, et al.
Publicado: (2013)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
por: Ling, James, et al.
Publicado: (2021)

Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis
por: Lau, E., et al.
Publicado: (2019)

Neutral protamine hagedorn/regular insulin in the treatment of inpatient hyperglycemia: Comparison of 3 basal-bolus regimens
por: Quintanilla-Flores, Dania Lizet, et al.
Publicado: (2017)

Long‐term field study of lispro and neutral protamine Hagedorn insulins treatment in dogs with diabetes mellitus
por: Kuzi, Sharon, et al.
Publicado: (2023)

Clinical experience of switching from biphasic human insulin to biphasic insulin aspart 30 in Indian patients with type 2 diabetes in the A(1)chieve study
por: Das, A. K., et al.
Publicado: (2015)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial
por: Bartley, P C, et al.
Publicado: (2008)

Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study
por: Wolnik, B., et al.
Publicado: (2022)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Agadir cohort of the A(1)chieve study
por: Boussouf, Hicham, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Marrakech cohort of the A(1)chieve study
por: Nawal, El Ansari
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Casablanca cohort of the A(1)chieve study
por: Farouqi, Ahmed, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Saiss cohort of the A(1)chieve study
por: Ajdi, Farida
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yanbu cohort of the A(1)chieve study
por: El Harby, Moody, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yemen cohort of the A(1)chieve study
por: Atef, Zayed, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Bahraini cohort of the A(1)chieve study
por: Hussein, Wiam Ibrahim, et al.
Publicado: (2013)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kuwait cohort of the A(1)chieve study
por: Daban, Alaa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c5s2v327a414vn4d6p12ltvnhc